On April 24, 2026 Amphista Therapeutics ("the Company" or "Amphista"), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue degraders, reported the presentation of new pre-clinical data on its orally bioavailable SMARCA2 and TEAD Targeted Glue programs at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, US, and publication in bioRxiv of the optimization of early TEAD Targeted Glues.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Selective SMARCA2 Targeted Glue degraders:

Robust SMARCA2 selectivity over SMARCA4 maintained over time
Deep degradation of SMARCA2 following oral delivery
New data from the DCAF16-dependent SMARCA2 program demonstrated deep in vivo degradation of SMARCA2 following oral dosing. In vivo SMARCA2 degradation translated into suppression of downstream biomarkers, including KRT80 and PLAU, reinforcing the therapeutic relevance of the approach. The program leverages insights gained from multiple high-resolution cryo-electron microscopy structures of the ternary complex, enabling improvements in the speed and depth of SMARCA2, as well as high degradation selectivity over the closely related SMARCA4 paralog. Together, these data support a best-in-class potential for Amphista’s SMARCA2 Targeted Glue degraders.

TEAD Targeted Glue degraders:

Oral in vivo tumor regression following intermittent dosing
bioRxiv publication on the rational and systematic optimization of early TEAD Targeted Glues
New data from the FBXO22-dependent TEAD program demonstrated anti-proliferative activity in mesothelioma cell lines, with synergistic efficacy observed in combination with osimertinib in vitro in an EGFR-mutant NSCLC model. Further data showcased how a degradation-based modality, combined with the long half-life of TEAD, drives extended pharmacodynamic effects, enabling an efficacious once-every-three-day dosing schedule and tumor regression in vivo in a mesothelioma xenograft model. The bioRxiv publication describes the rational and systematic optimization of early FBXO22 Cys326-mediated TEAD Targeted Glues, achieving enhanced degradation potency and kinetics compared to previously reported FBXO22-targeting approaches. These findings establish important design principles for this emerging degrader class and validate FBXO22-TEAD degradation as a therapeutically relevant approach for Hippo pathway-driven cancers, with promise in mesothelioma and combination strategies for EGFR-mutant NSCLC.

Dr. Louise Modis, Chief Executive Officer at Amphista Therapeutics, commented: "The positive preclinical data on two of our programs, SMARCA2 and TEAD, reflect the strength of our unique approach and proprietary technology, and the great progress we are making as we advance towards the clinic. We are actively seeking partners to collaborate on our SMARCA2 and TEAD programs as they progress towards candidate selection in the second half of 2026."

Today’s announcement builds on the progress Amphista has made since it disclosed its SMARCA2 and TEAD programs in September 2025 and follows the recent presentation of AMX-883, an orally bioavailable, highly potent and selective degrader of BRD9, at AACR (Free AACR Whitepaper) 2026.
BioRxiv publication details:

Title: Identification and SAR optimization of FBXO22-mediated TEAD Targeted Glue degraders

DOI: View Source

Poster presentations details:

Title: Rational development of novel DCAF16-mediated SMARCA2 selective Targeted Glues for the treatment of SMARCA4 deficient tumors

Session: Proximity-Induced Drug Discovery 1

Presenter: James Lynch, Senior Director Bioscience, Amphista Therapeutics

Title: Rational development of novel FBXO22-mediated TEAD Targeted Glues for Mesothelioma and NSCLC Treatment

Session: Targeted Protein Degradation and Induced Proximity

Presenter: Marta Carrara, Associate Director Bioscience, Amphista Therapeutics

(Press release, Amphista Therapeutics, APR 24, 2026, View Source [SID1234664752])

On April 24, 2026 Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, reported that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,700 shares of the Company’s stock (the "Inducement Grant") to newly hired employees on April 22, 2026 (the "Grant Date"), in connection with the commencement of employment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the "Plan") as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

(Press release, Aligos Therapeutics, APR 24, 2026, View Source [SID1234664750])

On April 24, 2026 Novartis reported it has withdrawn a European Medical Agency type II variation application for Pluvicto to treat adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)1 pre-chemotherapy, following CHMP feedback. The CHMP indicated that they would not support the application based on the control arm used in the PSMAfore study. The withdrawal is not related to the quality, efficacy or safety of Pluvicto and does not impact ongoing clinical trials, approved indications or pending regulatory submissions inside or outside the EU.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Importantly, the PSMAfore study that supported the application, was the basis for successful approval of Pluvicto in pre-chemotherapy mCRPC patients in the United States, Japan, and China. The value of Pluvicto in this population is also reflected in evidence-based recommendations from leading professional guidelines, including ESMO (Free ESMO Whitepaper), EAU, ASCO (Free ASCO Whitepaper) and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)2.

We are disappointed by this outcome and remain committed to advancing treatment options for people with prostate cancer.

(Press release, Novartis, APR 24, 2026, View Source [SID1234664748])

On April 23, 2026 Exicure, Inc. (Nasdaq: XCUR) reported that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.

Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.

Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, providing a foundation for further evaluation in hematologic indications such as AML and SCD. Based on its clinical profile to date, Burixafor may have potential applicability in additional hematologic indications.

The parties intend to conduct in vivo validation studies and, subject to further agreement, may advance selected programs into IND-enabling studies and clinical trials. The parties also intend to secure funding to support the advancement of future clinical development.

Further details regarding development plans, budget, intellectual property, and commercialization will be determined in a subsequent definitive agreement.

A representative of Exicure commented, "This agreement represents an important step in expanding the evaluation of Burixafor in combination approaches across multiple indications."

(Press release, Exicure, APR 23, 2026, View Source [SID1234664745])

On April 23, 2026 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, reported that topline results from the TEDOVA Phase 2 international clinical trial of Tedopi in Ovarian Cancer sponsored by ARCAGY-GINECO have been selected for an oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago, Illinois, United States (May 29 – June 2, 2026).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alexandra Leary, MD, PhD, Deputy Head of the Department of Medical Oncology at Gustave Roussy (Paris, France), oncologist specialising in gynaecological cancers, Chair of the GINECO group and Lead Investigator of the TEDOVA Phase 2 clinical trial of Tedopi, will present topline results from the TEDOVA trial evaluating Tedopi as a maintenance treatment of ovarian cancer.

"The neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial"

Rapid Oral Abstract
Session: Gynecologic Cancer – Subtrack: Ovarian Cancer
Abstract 5510
Room: E450
May 30, 2026, 8:06-8:12am CDT (3:06-3:12pm EST)
TEDOVA is a three-arm Phase 2 study evaluating Tedopi as a maintenance treatment, alone or in combination with anti-PD1 immune checkpoint inhibitor Keytruda (pembrolizumab), versus best supportive care in 185 patients in platinum-sensitive recurrent ovarian cancer with controlled disease after platinum-based chemotherapy who have already received both bevacizumab and a PARP (Poly ADP-Ribose Polymerase) inhibitor. The primary endpoint is the Progression Free Survival (PFS) of the maintenance of Tedopi, with a PD1 inhibitor, after platinum-based chemotherapy in relapsed ovarian cancer.
(NCT04713514).

(Press release, OSE Immunotherapeutics, APR 23, 2026, View Source [SID1234664744])